RT期刊文章SR电子T1加速脑损伤生物标志物在认知正常的老年人异常β-Amyloidosis乔(S04.006)摩根富林明神经病学神经病学FD Lippincott Williams &威尔金斯SP S04.006 OP S04.006 VO 80是7补充A1 David Knopman A1 Cli首页fford杰克A1 Heather Wiste A1 Stephen Weigand A1 Prashanthi Vemuri A1 Val劳A1 Kejal Kantarci A1马修Senjem A1杰弗里Gunter A1米歇尔Mielke A1玫瑰花蕾罗伯茨A1布拉德利Boeve A1罗纳德·彼得森年2013 UL //www.ez-admanager.com/content/80/7_Supplement/S04.006.abstract AB目的:测试假设的共同存在β-amyloid和脑损伤生物标志物与神经退行性病变加速度有关。背景:ß-amyloid的外观和脑损伤生物标志物在认知正常的人每个为认知障碍的未来发展带来风险由于阿尔茨海默病(AD),但他们的相互作用了解甚少。设计/方法:受试者191认知正常(CN)的梅奥诊所研究人员老化先生接受了谁,FDG PET和加以PET成像> 1年至少两次分开。受试者分组根据NIA-AA临床前广告的建议标准:β-amyloidosis定义为加以宠物SUVr > 1.5单独或与脑损伤定义为海马萎缩或广告FDG代谢减退。我们还包括MCI和痴呆患者(n = 26)的梅奥诊所研究老化或梅奥老年中心曾可比成像和谁都加以宠物SUVr > 1.5。结果:有25个CN科目高加以保留和低海马体积或FDG代谢减退(临床前广告阶段2 + 3);他们有一个更大的海马体积损失比其他CN科目(p < 0.01),与MCI和痴呆的速度由于广告参与者。临床前的广告阶段2 + 3受试者低基线FDG代谢减退但没有显示FDG代谢减退率更大。较高的纵向壁发生在主题与MCI和下降,由于广告更是如此,痴呆。结论:较高的海马体积损失发生在CN人异常β-amyloid和脑损伤的生物标志物在基线水平相比其他CN参与者只有一个或者没有异常生物标记类。更高的FDG代谢减退率没有明显在我们CN参与者,可能以后的广告病态级联事件。支持:国家卫生研究院的基金P50 AG16574 U01 AG06786, R01 AG11378, R01 AG41851, MN合作生物技术和医学基因组学,通用电气医疗集团,埃尔希和马文Dekelboum家庭基金会和罗伯特·h·克拉丽斯史密斯和阿比盖尔范布伦阿尔茨海默病梅奥基金会的研究项目。披露:Knopman博士已经收到个人赔偿与礼来公司和公司活动。Knopman博士已经收到了个人在一篇社论中补偿神经病学的能力。首页 Dr. Knopman has received research support from TauRx. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Company. Dr. Jack has received research support from Pfizer Inc, Allon, and Baxter. Dr. Jack has received research support from Allon and Baxter. Dr. Wiste has nothing to disclose. Dr. Weigand has nothing to disclose. Dr. Vemuri has nothing to disclose. Dr. Lowe received personal compensation for consulting from Bayer Pharmaceuticals. Dr. Lowe received research grants from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Kantarci has received compensation from Takeda Global Research & Development Center for serving as an advisory board member for research support. Dr. Senjem has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Mielke has nothing to disclose. Dr. Roberts has received research support from Abbott Laboratories. Dr. Boeve has received research support from Cephalon, Inc.; Allon Therapeutics; and GE Healthcare. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, GE Healthcare, and Novartis.Tuesday, March 19 2013, 1:00 pm-2:45 pm